Accepted Manuscript

Discovery of a novel series of hDHODH inhibitors with anti-pulmonary fibrotic activities

Kuan Lu, Yanfang Zhao, Guodong Wu, Hao Hu, Mingzhong Wang, Guowei Gong, Yuyang Jiang

PII:	\$0045-2068(18)31236-7
DOI:	https://doi.org/10.1016/j.bioorg.2019.01.011
Reference:	YBIOO 2715
To appear in:	Bioorganic Chemistry
Received Date:	30 October 2018
Revised Date:	4 January 2019
Accepted Date:	6 January 2019



Please cite this article as: K. Lu, Y. Zhao, G. Wu, H. Hu, M. Wang, G. Gong, Y. Jiang, Discovery of a novel series of hDHODH inhibitors with anti-pulmonary fibrotic activities, *Bioorganic Chemistry* (2019), doi: https://doi.org/10.1016/j.bioorg.2019.01.011

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Discovery of a novel series of hDHODH inhibitors with

anti-pulmonary fibrotic activities

Kuan Lu^{a,b}, Yanfang Zhao^a, Guodong Wu^a, Hao Hu^a, Mingzhong Wang^b, Guowei Gong^e* and Yuyang Jiang^{*a,c,d}

^a Department of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, PR China

^b Shenzhen Kivita Innovative Drug Discovery Institute, Shenzhen, 518057, PR China

^c National & Local United Engineering Lab for Personalized Anti-tumor Drugs, The Graduate School at Shenzhen, Tsinghua University, Shenzhen, 518055, PR China

^d Department of Pharmacology and Pharmaceutical Sciences, School of Medicine, Tsinghua University, Beijing, 100084, PR China

^e Department of bioengineering, Zunyi Medical University, Zhuhai Campus, Zhuhai 519041, Guangdong, China

*Corresponding author.

E-mail address: jiangyy@sz.tsinghua.edu.cn (Yuyang Jiang); amygong90@hotmail.com (Guowei Gong).

Abstract

Human dihydroorotate dehydrogenase (hDHODH) is a flavin-dependent enzyme essential to pyrimidine *de novo* biosynthesis, which serves as an attractive therapeutic target for the treatment of autoimmune disorders. A novel series of hDHODH inhibitors was developed based on a lead which was obtained by a medicinal chemistry exploration. Most compounds showed moderate to significant potency against hDHODH, compounds **5d**, **5e**, and **6a** effectively inhibited the activities of hDHODH with IC₅₀ values from 0.9 to 2.8 μ M. Further studies showed that compound **5e** also effectively suppressed proliferation of the activated PBMCs (IC₅₀= 20.35 μ M). Surprisingly, compound **5e** also showed anti-pulmonary fibrotic activity similar to that of pirfenidone *in vitro* assay. Therefore, compound **5e** might have potential to be developed as a novel hDHODH inhibitors for autoimmune diseases therapy.

Keywords: Human dihydroorotate dehydrogenase (hDHODH) inhibitors; Autoimmune diseases; Drug design; Anti-pulmonary fibrotic activity

1. Introduction

Human dihydroorotate dehydrogenase (hDHODH) is a flavin-dependent enzyme essential to pyrimidine *de novo* biosynthesis. It has been identified as a therapeutic target for the treatment of autoimmune disorders such as rheumatoid arthritis and multiple sclerosis [1-3]. Leflunomide (**Fig.1a**) and Brequinar (**Fig.1c**) are two representative hDHODH inhibitors. The former was approved more than 20 years ago for the treatment of rheumatoid arthritis [1]. leflunomide acts as a prodrug and is rapidly converted into its active metabolite teriflunomide (**Fig.1b**) which was approved for treatment of multiple sclerosis. While, brequinar was initially evaluated in clinical trials as a potential anticancer agent. However, it was discarded due to severe side effects [4]. Recently, Johann Leban [5] and Honglin Li [6] respectively reported several hDHODH inhibitors which bore thiophene carboxylic acid (**Fig.1d**) and thiazole-scaffold (**Fig.1e**) with IC₅₀ 1 nM and 18 nM. However, despite recent efforts, the quest to explore the therapeutic potential of hDHODH inhibitors remains an urgent area of research.



Fig. 1. Selected Structures of the Reported DHODH Inhibitors

In our previous studies, compound **f** (**Fig.2**) has been identified as a potential hDHODH inhibitor ($IC_{50} = 1.5 \mu M$). Docking analysis showed that compound **f** adopted a binding mode similar with brequinar: The amide group forms two hydrogen bonds with residues Gln47 and Arg136 of the enzyme and the terminal phenyl ring extends into the hydrophobic pocket.

In order to improve the potency, we described a novel series of hDHODH inhibitors designed by replacing the phenyl moiety (**Fig.2** blue part) with thiophene which exists in the effective hDHODH inhibitor compound **d**. The most promising compound **5e** (IC₅₀ = 0.9 μ M) exhibited 1.6-fold more potent than compound **f** and displayed efficient anti-inflammation effect. Unexpectedly, some of the target compounds also showed anti-pulmonary fibrotic activities. It suggested that they might be developed as novel immune-suppressants without drug-induced pulmonary fibrotic.



Fig. 2. Design strategy of the target compounds.

2. Results and discussion

2.1 Chemistry

The synthetic procedure for the target compounds is described in **Scheme 1**. 3-amino-2-thiophenecarboxylate methyl ester **1** was treated with NaNO₂ to yield the diazonium salt, which were not isolated but directly treated with NaN₃ to obtain azido derivative **2** [7] which was converted to intermediate **3** by hydrolysis. Intermediate **3** was treated with SOCl₂ under reflux to obtain 2-theonyl chloride derivative which reacted with ammonia or cyclopropylamine to give the intermediates **4a-4b** [8]. Intermediates **7a-n** were synthesized by reacting suitable aniline or phenol with propargyl bromide [9-11]. The target compounds were yielded by click chemistry with copper-catalyzed alkyne-azide 1,3-dipolar cycloaddition (CuAAC) [12] between intermediates **2**, **3**, **4a-4b** and intermediates**7a-o** at room temperature. The target compounds were purified by column chromatography on silica gel. The chemical structures of the target compounds were confirmed by ¹H NMR, ¹³C NMR and ESI-MS.



Scheme 1. Reagents and conditions: (i) NaNO₂, HCl; NaN₃, 1 h; (ii) NaOH, EtOH/H₂O reflux; (iii) a: SOCl₂, reflux, 5 h; b: NH₃.H₂O/ cyclopropylamine, rt, 2h; (iv) alkyne, Sodium ascorbate, CuSO₄, t-BuOH/H₂O (1:1), rt, 3-4h. (v) a: X=NH, 3-bromopropyne, K₂CO₃, DMF, rt, overnight; b: X=O, 3-bromopropyne, K₂CO₃, MeCN, reflux.

In order to determine the stereochemistry of the target compounds, the NOESY experiment of compound **5e** was carried out, and an evident NOE signal was observed between the proton (d, 7.42 ppm) on the 4-postion of the thiophene amide moiety and the proton (s, 8.70 ppm) on the 1,2,3-triazole, which existed only in the **A-5e** form due to the appropriate intramolecular H–H distance (**Fig. 3** and see Supporting Information).



Fig. 3. NOESY effect of the representative compound 5e.

2.2. Biological evaluation

2.2.1Inhibition of hDHODH and structure-activity relationships

To get a preliminary insight into SARs, the thiophene derivatives with different R group were synthesized and evaluated for enzyme inhibition assay. Human DHODH inhibition assay was conducted using chromogen reduction method with 2,6-dichlorophenolindophenol (DCIP). Dihydroorotate (DHO) oxidation and coenzyme Q (CoQ) reduction was coupled with chromogen reduction. Enzyme inhibition was resulted in loss of chromogen absorbance at 600 nm. The preliminary activities were measured at 10 μ M concentration of synthesized compounds. The results (**Table 1**). showed that compound **4c** (R=NH₂) exhibited higher potency than **2a** and **3a**.

Table 1 Inhibitory activities of the compounds against hDHODH under 10 µM concentration.



a SD: standard deviation.

Due to the relatively weak activity of 4c, further modification of the target compounds with different groups was undertaken. The results (**Table 2**) showed that the position and property of R_2 groups had a dramatic impact on activities against

hDHODH. When **X** is oxygen atom, the incorporation of a polar group such as CN or CF₃ group to 4-position of the terminal phenyl group led to a significant improvement in potency (**5d**, **5e** vs **4c**). However, compounds **5a** and **5c** which possessed 4-position halogen were inactive. Shifting fluorine from 4-position (**5a**) to 3-position (**5b**) increased the activity, while introduction CF₃ group on the 3-position showed a significant decreased potency (**5g** vs **5e**). Besides, conversion of the R₁ substituted phenyl ring to naphthalene (**5j**) also obtained low potency. When X is nitrogen atom, compound **6a** and **6c** showed high potency (**6a**, **6c** vs **4c**), compounds **6e** and **6f** with 3,4-disubstituted halogen were inactive. Moreover, the introduction of cyclopropyl at R₁ result in the decline of activities against hDHODH (**5f** vs **5e**, **6d** vs **4c**) The results indicated that amide without substitution and a suitable substitution on the terminal phenyl moiety were crucial for high potency.

			O ^R ₁ → NH		
		S	N ^N N X	R ₂	
	Compound	Х	R ₁	R ₂	% Inhibition \pm SD ^a at 10 μ M.
	5a	0	Н	4-F	NA
	5b	0	Н	3-F	49 ± 0
	5c	0	Н	4-Br	NA
	5d	0	Н	4-CN	86 ± 4
	5e	0	Н	$4-CF_3$	89 ± 0
	5f	0	cyclopropyl	$4-CF_3$	49 ± 4
	5g	0	Н	3-CF ₃	20 ± 11
	5h	0	Н	3,4-2F	NA
	5i	0	Н	2-Br-4-F	49 ± 0
0	5j	0	Н	X CO	25 ± 11
	6a	Ν	Н	4-F	83 ± 4
	6b	Ν	Н	4-Br	57 ± 4
	6с	Ν	Н	4-OMe	72 ± 0
	6d	Ν	cyclopropyl	$4-CF_3$	12 ± 7
	6e	Ν	Н	3,4-2F	NA
	6f	Ν	Н	3-Cl-4-F	NA

Table 2 Inhibitory activities of the compounds against hDHODH under 10 µM concentration

a SD: standard deviation.

Based on the preliminary assays, four compounds which showed significant potency were selected for further test IC_{50} values against hDHODH *in vitro*. The results were summarized in **Table 3**. As predicted, all of the selected compounds

displayed good to significant potency against hDHODH with IC₅₀ values ranging from 0.9 to 4.6 μ M and compound **5e** (IC₅₀ = 0.9 μ M) exhibited relatively higher potency than teriflunomide.

Table 3 IC ₅₀ values of synthesized derivatives against hDHODH			
Compound	$IC_{50}{}^{a}(\mu M)$	Compound	$IC_{50}^{a}(\mu M)$
5d	2.8	6a	4.6
5e	0.9	6c	2.7
Teriflunomide ^b	1.1		
means of two indep	pendent experin	nents.	
ve control.			
osuppression as	say and meta	bolic stability	, 9

a Values are the means of two independent experiments.

b Used as positive control.

2.2.2 Immunosuppression assay and metabolic stability

Based on the enzymatic assays, compound 5e was selected for further study the immunosuppressive effect on the proliferation of stimulated peripheral blood mononuclear cells (PBMCs) compared with teriflunomide. As shown in Table 4, compound 5e was found to act similarly to teriflunomide, inhibiting activated PBMCs proliferation (IC₅₀ = 20.35 μ M). Moreover, we performed the study of **5e** in incubation with human liver microsomes in vitro. The studies revealed that 5e possessed high $T_{1/2}$ >120 min and exhibited moderate CL. It demonstrated that 5e was stable in human liver microsomes.

Table 4 Infibition of promeration of sumulated F Divics and metabolic stability	Table 4 Inhibition	of proliferation	n of stimulated	PBMCs and	l metabolic	stability
---	--------------------	------------------	-----------------	-----------	-------------	-----------

Compound	$IC_{50}^{a}(\mu M)$	T _{1/2} ^c (min)	CL(µL/min/mg)
5e	20.35	198.2	7.0
teriflunomide ^b	14.17		

a Values are the means of two independent experiments.

b Used as positive control.

c Conducted in human liver microsomes with final liver microsomal protein (0.5mg/mL).

2.2.3 anti-pulmonary fibrotic assay

Drug-induced interstitial lung disease (ILD), particularly pulmonary fibrosis, is a serious clinical concern. For example, hDHODH inhibitor leflunomide, imatinib and gefitinib, are known to induce ILD (pulmonary fibrosis). it can lead to patient death, thereby restricting the therapeutic use of these drugs [13-15]. Recently, a rapid method for anti-fibrotic drugs screening based on cellular stiffness was developed [16]. A549 cells in vitro were stimulated with transforming growth factor- β 1 (TGF- β 1). It led the increase of the cellular stiffness which may be reversed by the compounds with anti-pulmonary fibrotic activities. The alteration of cellular stiffness was measured utilizing atomic force microscopy (AFM). The anti-pulmonary fibrotic activities of compound 5d, 5e and 6c were evaluated by the method above and anti-pulmonary fibrotic drug pirfenidone was used as positive control. The results are summarized in Table 5. Compared with pirfenidone, compound 5e exhibited best

potency which could reduce the cellular stiffness of TGF- β 1 stimulated A549 cells from 9.25 Kpa to 6.23 Kpa.

Table 5 Altera	ation of central still	liess of 101-p1	stimulated AS47 cells
Compound	Stiffness ^a (Kpa)	Compound	Stiffness ^a (Kpa)
5d	6.40±1.79	6с	7.29±1.51
5e	6.23±1.58	Control ^b	4.48±1.96
Model ^c	9.25±1.02	pirfenidone ^d	6.09±0.30

Table 5 Alteration of cellular stiffness of TGF-β1 stimulated A549 cells

a Values are the means of at least two independent experiments

b A549 cells without any stimulation

c TGF-β1 stimulated A549 cells without any compound

d Used as positive control.

2.2.4 Binding mode analysis

To further elucidate the binding mode, molecular docking of the potent compound **5e** was performed in the binding site cavity of hDHODH. Crystal structure of hDHODH (PDB ID: 1D3G) [17] and the target compound was pretreated by Discovery Studio 3.0. All docking runs were utilizing CDOCKER protocol of Discovery Studio 3.0 systems. The image files were generated by the PyMOL (The PyMOL Molecular Graphics System, Version 1.4.1. Schrödinger, LLC).



Fig. 4. Docking mode of compound **5e** with hDHODH (PDB ID:1D3G) a representation of the overlap of docking model of **5e** (blue) with brequinar (brown) in the binding site cavity of hDHODH. For clarity, only interacting residues are displayed. The H-bond (Green arrows) are displayed as dotted arrows.

Fig.4 shows the binding model overlay of the binding model of compound **5e** with brequinar. It can be observed that compound **5e** adopted a brequinar-like binding mode with matching occupancy of the hydrophobic pocket. The carboxyl group on the thiophene amide moiety formed two hydrogen bonds with residues Gln47 and Arg136. However, unlike brequinar, sulfur atom of thiophene moiety was founded to reach the

small hydrophobic pocket and the hydrogen on the amide nitrogen atom formed additional hydrogen bond with residues Thr360 which would be beneficial to increase the binding affinity.

3. Conclusions

A previously discovered hDHODH inhibitor was further improved by replacing the phenyl moiety by thiophene, a series of thiophene derivatives were designed, synthesized and evaluated as hDHODH inhibitors. It led us to discover compound **5e** which displayed higher potency than teriflunomide. Compound **5e** also showed high antiproliferative activity against stimulated PBMCs and possessed acceptable metabolic stability. Besides, compound **5e** reduced the stiffness of TGF- β 1 stimulated A549 cells similar with anti-pulmonary fibrotic drug pirfenidone. Taken together, compound **5e** may serve as a lead compound for the development of novel immunosuppressant without inducing pulmonary fibrotic.

Experimental section

4.1. Chemistry

Reagents and solvents were obtained from commercial sources and used without further purification. Flash chromatography was performed using silica gel (300–400 mesh) from Qingdao Ocean Chemicals (Qingdao, Shandong, China). All reactions were monitored by TLC on silica gel plates. Melting points were determined on a Büchi Melting Point B-540 apparatus (Büchi Labortechnik, Flawil, Switzerland). The ¹H and ¹³C NMR were recorded on Bruker ARX-400 or ARX-600 spectrometer (Bruker Bioscience, Billerica, MA, USA) with TMS as an internal standard. Mass spectra (MS) were measured in ESI mode on an Agilent 1100 LC-MS (Agilent, Palo Alto, CA, USA). Elemental analysis was determined on a Carlo-Erba 1106 Elemental analysis instrument (Carlo Erba, Milan, Italy). Propargyl intermediate (**7a-7o**) were prepared following already described procedures [9-11].

4.1.1. Preparation of 3-azidothiophene-2-carboxylate methyl ester (2)

3-amino-2-thiophenecarboxylate methyl ester **1** (0.06 mol) was dissolved in concentrated hydrochloric acid (15 mL), and ice (45 g) was added. When the mixture was cooled to 0 °C, saturated sodium nitrite (5.2 g, 0.075 mol) aqueous solution was added keeping the temperature below 5 °C. After 10 min, resinous sediment (if it was formed) should be filtered. To the filtrated solution of the diazonium salt, sodium azide (3.9 g; 0.06 mol) in 5 mL of water was added dropwise. The solution was left for 30 min at room temperature and the azide was filtered as a white solid which was used without subsequent cleaning. Yield: 80% (8.7g) m.p.:170.6-172.3°C. ¹H NMR (400 MHz, DMSO-d₆) $\delta_{\rm H}$ 7.95 (d, J = 5.4 Hz, 1H), 7.17 (d, J = 5.4 Hz, 1H), 3.79 (s, 3H). ¹³C NMR (100 MHz, DMSO-d₆) $\delta_{\rm C}$ 161.15, 142.21, 133.45, 123.74, 116.78, 52.51. ESI-MS m/z: 206.3 [M+Na]⁺.

4.1.2. Preparation of 3-azidothiophene-2-carboxylic acid (3) Intermediate 2 (8.0 g, 0.043 mol) and NaOH (5.1 g, 0.13 mol) were added to a solution of EtOH and H₂O (80 mL, EtOH:H₂O = 5:1). The mixture was stirred at 90° C for 2h. Upon cooling to room temperature, ethanol was removed under vacuum, and then H₂O (40mL) was added to the mixture. The solution was adjusted to pH 2-3 with 3N HCl, and then the resulting precipitate was filtered and dried under reduced pressure to afford a brown solid. Yield: 82% (5.9g) m.p.:137.2-139.1°C. ¹H NMR (400 MHz, DMSO-d₆) $\delta_{\rm H}$ 13.16 (s, 1H), 7.88 (d, J = 5.4 Hz, 1H), 7.10 (d, J = 5.4 Hz, 1H). ¹³C NMR (100 MHz, DMSO-d₆) $\delta_{\rm C}$ 162.25, 141.34, 132.50, 123.87,112.64. ESI-MS m/z: 168.2 [M-H]⁻.

4.1.3. General procedure for preparation of 3-azidothiophene-2-carboxamide (4a-4b)

At room temperature, $SOCl_2$ (20 mL) and 2 drops of DMF were added to intermediate **3** (4g, 30.6 mmol) and the mixture was refluxed for 4 h. The excess $SOCl_2$ was evaporated. Then, 25% $NH_3.H_2O$ (20 mL) was added to the residue at 0 °C and the mixture was stirred for 2-3h. A white precipitate was isolated by filtration. The precipitate was washed with water and dried in vacuo to afford 2-azidobenzamide.

4.1.3.1. 3-azidothiophene-2-carboxamide (4a)

Yield: 72% (2.8 g), pale yellow solid, m.p.:151.3-152.4°C. ¹H NMR (400 MHz, DMSO-d₆) $\delta_{\rm H}$: 7.83 (d, J = 5.4 Hz, 1H), 7.70 (s, 1H), 7.24 (d, J = 5.4 Hz, 1H), 7.15 (s, 1H); ¹³C NMR (100 MHz, DMSO-d₆) $\delta_{\rm C}$ 162.01, 136.56, 131.29, 123.80, 122.13; ESI-MS m/z: 169.2 [M+H]⁺.

4.1.3.2. 3-azido-*N*-cyclopropylthiophene-2-carboxamide (**4b**)

Yield: 76% (3.7 g), yellow solid, m.p.:137.5-139.3°C. ¹H NMR (600 MHz, DMSO-d₆) $\delta_{\rm H}$: 7.82 (d, J = 5.4 Hz, 1H), 7.66 (s, 1H), 7.21 (d, J = 5.4 Hz, 1H), 2.78 (m, 1H), 0.73 – 0.69 (m, 2H), 0.61 – 0.58 (m, 2H); ¹³C NMR (100 MHz, DMSO-d₆) $\delta_{\rm C}$ 161.62, 136.06, 130.82, 123.61, 122.20, 23.34, 6.58; ESI-MS m/z: 209.3 [M+H]⁺.

4.1.4. General procedure for preparation of the target compounds. (2a, 3a,4c, 5a-5i, 6a-6f)

A mixture of the appropriate azido derivative (0.2g, 1.2 mmol), the appropriate alkyne derivative (1.4 mmol), copper sulphate (0.1 mmol) and sodium ascorbate (0.5 mmol) in 4 mL tBuOH/H₂O (1:1) were stirred at room temperature for 3-4h. The reaction mixture was diluted with water and the precipitate was collected by filtration. After being washed with cold water (2×5 mL), the precipitate was dried under vacuum. when necessary, they were purified by chromatograpy.

4.1.4.1.3-(4-(((4-(trifluoromethyl)phenyl)amino)methyl)-1H-1,2,3-triazol-1-yl) thiophene-2-carboxylate methyl ester (**2a**)

Yield: 77% (0.32g), White solid, M.p.: 140.2-141.8°C. ¹H NMR (600 MHz, DMSO-d₆) $\delta_{\rm H}$: 8.51 (s, 1H), 8.10 (d, J = 5.3 Hz, 1H), 7.48 (d, J = 5.3 Hz, 1H), 7.38 (d, J = 8.7 Hz, 2H), 6.96 (t, J = 5.9 Hz, 1H), 6.79 (d, J = 8.7 Hz, 2H), 4.46 (d, J = 5.9 Hz, 2H), 3.68 (s, 3H); ¹³C NMR (100 MHz, DMSO-d₆) $\delta_{\rm C}$: 156.74, 147.91, 141.19, 134.39, 129.46, 123.43, 122.85, 122.81, 122.12, 119.59, 119.57, 108.39, 49.02, 34.41;

ESI-MS m/z: 383.3 $[M+H]^+$. Anal. calcd. For $C_{16}H_{13}F_3N_4O_2S$ (%):C, 50.26; H, 3.43; N, 14.65. Found (%): C, 50.23; H, 3.47; N, 14.59.

4.1.4.2.3-(4-(((4-(trifluoromethyl)phenyl)amino)methyl)-1H-1,2,3-triazol-1-yl) thiophene-2-carboxylic acid (**3a**)

Yield: 68% (0.29 g), White solid, M.p.: 189.1-191.0°C. ¹H NMR (600 MHz, DMSO-d₆) $\delta_{\rm H}$: 13.54 (s, 1H), 8.53 (s, 1H), 8.02 (d, J = 5.3 Hz, 1H), 7.44 (d, J = 5.3 Hz, 1H), 7.38 (d, J = 8.5 Hz, 2H), 6.94 (t, J = 5.4 Hz, 1H), 6.78 (d, J = 8.5 Hz, 2H), 4.44 (d, J = 5.4 Hz, 2H); ¹³C NMR (100 MHz, DMSO-d₆) $\delta_{\rm C}$: 161.54, 151.75, 144.74, 137.65, 132.39, 127.22, 126.65, 126.61, 126.05, 124.87, 116.10, 112.15, 38.25; ESI-MS m/z: 367.0 [M-H]⁻. Anal. calcd. For C₁₅H₁₁F₃N₄O₂S (%):C, 48.91; H, 3.01; N, 15.21. Found (%): C, 48.95; H, 2.97; N, 15.23.

4.1.4.3.3-(4-(((4-(trifluoromethyl)phenyl)amino)methyl)-1H-1,2,3-triazol-1-yl) thiophene-2-carboxamide (**4c**)

Yield: 75% (0.33 g), White solid, M.p.: 182.7-184.1°C. ¹H NMR (600 MHz, DMSO-d₆) $\delta_{\rm H}$: 8.49 (s, 1H), 7.88 (d, J = 5.3 Hz, 1H), 7.84 (s, 1H), 7.69 (s, 1H), 7.41 (d, J = 5.3 Hz, 1H), 7.39 (d, J = 8.6 Hz, 2H), 6.93 (t, J = 5.7 Hz, 1H), 6.79 (d, J = 8.6 Hz, 2H), 4.44 (d, J = 5.7 Hz, 2H); ¹³C NMR (100 MHz, DMSO-d₆) $\delta_{\rm C}$: 161.97, 151.79, 145.33, 133.99, 129.12, 129.05, 126.67, 126.64, 125.71, 125.16, 112.16, 99.99, 38.26; ESI-MS m/z: 390.3 [M+Na]⁺. Anal. calcd. For C₁₅H₁₂F₃N₅OS (%):C, 49.04; H, 3.29; N, 19.06. Found (%): C, 49.01; H,3.27; N, 19.09.

4.1.4.4.3-(4-((4-fluorophenoxy)methyl)-1H-1,2,3-triazol-1-yl)thiophene-2-carboxami de (5a)

Yield: 81% (0.30 g), White solid, M.p.: 136.5-137.9°C. ¹H NMR (600 MHz, DMSO-d₆) $\delta_{\rm H}$: 8.68 (s, 1H), 7.90 (d, J = 5.3 Hz, 1H), 7.86 (s, 1H), 7.68 (s, 1H), 7.44 (d, J = 5.3 Hz, 1H), 7.18 – 7.14 (m, 2H), 7.13 – 7.09 (m, 2H), 5.21 (s, 2H); ¹³C NMR (100 MHz, DMSO-d₆) $\delta_{\rm C}$: 161.92, 158.37, 154.85, 142.93, 134.05, 129.46, 128.96, 126.83, 125.87, 116.58, 116.35, 61.91; ESI-MS m/z: 341.5 [M+Na]⁺. Anal. calcd. For C₁₄H₁₁FN₄O₂S (%):C, 52.82; H, 3.48; N, 17.60. Found (%): C, 52.85; H, 3.46; N, 17.63.

4.1.4.5.3-(4-((3-fluorophenoxy)methyl)-1H-1,2,3-triazol-1-yl)thiophene-2-carboxami de (**5b**)

Yield: 84% (0.32 g), Brown solid, M.p.: 168.1-169.2°C. ¹H NMR (600 MHz, DMSO-d₆) $\delta_{\rm H}$: 8.69 (s, 1H), 7.89 (d, J = 5.3 Hz, 1H), 7.86 (s, 1H), 7.67 (s, 1H), 7.44 (d, J = 5.3 Hz, 1H), 7.34 (dd, J = 15.5, 8.1 Hz, 1H), 6.99 (m, 1H), 6.92 (m, 1H), 6.80 (m, 1H), 5.24 (s, 2H); ¹³C NMR (100 MHz, DMSO-d₆) $\delta_{\rm C}$: 161.90, 159.97, 142.59, 134.07, 131.25, 131.15, 129.44, 128.93, 126.98, 125.88, 111.62, 108.04, 102.78, 61.69; ESI-MS m/z: 341.3 [M+Na]⁺. Anal. calcd. For C₁₄H₁₁FN₄O₂S (%):C, 52.82; H, 3.48; N, 17.60. Found (%): C, 52.83; H, 3.50; N, 17.58.

4.1.4.6.3-(4-((4-bromophenoxy)methyl)-1H-1,2,3-triazol-1-yl)thiophene-2-carboxami de (**5c**)

Yield: 85% (0.38 g), White solid, M.p.: 134.2-134.9°C. ¹H NMR (600 MHz, DMSO-d₆) $\delta_{\rm H}$: 8.68 (s, 1H), 7.89 (d, J = 5.3 Hz, 1H), 7.85 (s, 1H), 7.66 (s, 1H), 7.48 (d, J = 9.0 Hz, 2H), 7.43 (d, J = 5.3 Hz, 1H), 7.06 (d, J = 9.0 Hz, 2H), 5.22 (s, 2H); ¹³C NMR (100 MHz, DMSO-d₆) $\delta_{\rm C}$: 161.90, 157.81, 142.69, 134.06, 132.65, 129.46, 128.95, 126.94, 125.87, 117.57, 112.86, 61.59; ESI-MS m/z: 401.4 [M+Na]⁺. Anal. calcd. For C₁₄H₁₁BrN₄O₂S (%):C, 44.34; H, 2.92; N, 14.77. Found (%): C, 44.31; H, 2.93; N, 14.79.

4.1.4.7.

3-(4-((4-cyanophenoxy)methyl)-1H-1,2,3-triazol-1-yl)thiophene-2-carboxamid e (**5d**)

Yield: 91% (0.35 g), Brown solid, M.p.: 190.3-192.1 °C. ¹H NMR (600 MHz, DMSO-d₆) $\delta_{\rm H}$: 8.71 (s, 1H), 7.89 (d, J = 5.1 Hz, 1H), 7.85 (s, 1H), 7.81 (d, J = 8.5 Hz, 2H), 7.66 (s, 1H), 7.43 (d, J = 5.1 Hz, 1H), 7.27 (d, J = 8.5 Hz, 2H), 5.34 (s, 2H); ¹³C NMR (100 MHz, DMSO-d₆) $\delta_{\rm C}$: 161.93, 161.89, 142.20, 134.70, 134.08, 129.47, 128.95, 127.20, 125.89, 119.55, 116.34, 103.73, 61.71; ESI-MS m/z: 326.4 [M+H]⁺. Anal. calcd. For C₁₅H₁₁N₅O₂S (%):C, 55.38; H, 3.41; N, 21.53. Found (%): C, 55.41; H, 3.38; N, 21.55.

4.1.4.8.

3-(4-((4-(trifluoromethyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)thiophene-2-carboxa mide (**5e**)

Yield: 86% (0.38 g), Yellow solid, M.p.: 147.9-149.2 °C. ¹H NMR (600 MHz, DMSO-d₆) $\delta_{\rm H}$: 8.71 (s, 1H), 7.90 (d, J = 5.2 Hz, 1H), 7.86 (s, 1H), 7.69 (d, J = 8.4 Hz, 3H), 7.44 (d, J = 5.2 Hz, 1H), 7.28 (d, J = 8.4 Hz, 2H), 5.33 (s, 2H); ¹³C NMR (100 MHz, DMSO-d₆) $\delta_{\rm C}$: 161.34, 160.77, 141.89, 133.51, 128.89, 128.38, 126.91, 126.87, 126.52, 125.32, 121.56, 115.19, 61.08; ESI-MS m/z: 369.5 [M+H]⁺. Anal. calcd. For C₁₅H₁₁F₃N₄O₂S (%):C, 48.91; H, 3.01; N, 15.21. Found (%): C, 48.87; H, 3.04; N, 15.19.

4.1.4.9.

N-cyclopropyl-3-(4-((4-(trifluoromethyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)thiop hene-2-carboxamide (**5f**)

Yield: 87% (0.42 g), Yellow solid, M.p.: 146.3-148.5 °C. ¹H NMR (600 MHz, DMSO-d₆) $\delta_{\rm H}$: 8.65 (s, 1H), 8.50 (d, J = 3.1 Hz, 1H), 7.88 (d, J = 5.3 Hz, 1H), 7.69 (d, J = 8.7 Hz, 2H), 7.45 (d, J = 5.3 Hz, 1H), 7.28 (d, J = 8.7 Hz, 2H), 5.33 (s, 2H), 2.71 (m, 1H), 0.65 – 0.61 (m, 2H), 0.46 – 0.42 (m, 2H); ¹³C NMR (100 MHz, DMSO-d₆) $\delta_{\rm C}$: 161.60, 161.31, 142.45, 133.82, 129.05, 128.70, 127.47, 127.44, 126.70, 125.25, 121.96, 115.75, 61.61, 23.37, 6.10; ESI-MS m/z: 409.5[M+H]⁺. Anal. calcd. For C₁₈H₁₅F₃N₄O₂S (%):C, 52.94; H, 3.70; N, 13.72. Found (%): C, 52.95; H, 3.72; N, 13.69.

4.1.4.10.

3-(4-((3-(trifluoromethyl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)thiophene-2-carboxa mide (**5g**)

Yield: 78% (0.34 g), White solid, M.p.: 142.7-144.3°C. ¹H NMR (600 MHz, DMSO-d₆) $\delta_{\rm H}$: 8.71 (s, 1H), 7.91 (d, J = 5.3 Hz, 1H), 7.87 (s, 1H), 7.68 (s, 1H), 7.57 (t, J = 7.9 Hz, 1H), 7.45 (d, J = 5.3 Hz, 1H), 7.42 (m, 2H), 7.34 (d, J = 7.9 Hz, 1H), 5.34 (s, 2H); ¹³C NMR (100 MHz, DMSO-d₆) $\delta_{\rm C}$: 161.91, 158.81, 142.56, 134.07, 131.24, 130.67, 129.43, 128.95, 127.02, 125.87, 123.11, 119.53, 118.00, 111.92, 61.76; ESI-MS m/z: 369.5[M+H]⁺. Anal. calcd. For C₁₅H₁₁F₃N₄O₂S (%):C, 48.91; H,3.01; N, 15.21. Found (%): C, 48.93; H, 3.02; N,15.24.

4.1.4.11.

3-(4-((3,4-difluorophenoxy)methyl)-1H-1,2,3-triazol-1-yl)thiophene-2-carboxamide (5h)

Yield: 82% (0.33 g), White solid, M.p.: 145.8-147.6°C. ¹H NMR (600 MHz, DMSO-d₆) δ_{H} : 8.68 (s, 1H), 7.89 (d, J = 5.3 Hz, 1H), 7.85 (s, 1H), 7.66 (s, 1H), 7.43 (d, J = 5.3 Hz, 1H), 7.38 (dd, J = 19.8, 9.4 Hz, 1H), 7.25 (m, 1H), 6.91 (m, 1H), 5.22 (s, 2H).; ¹³C NMR (100 MHz, DMSO-d₆) δ_{C} : 161.33, 154.59, 154.51, 141.89, 133.51, 128.88, 128.37, 126.45, 125.32, 117.51, 111.07, 111.00, 104.40, 61.60; ESI-MS m/z: 337.4 [M+H]⁺. Anal. calcd. For C₁₄H₁₀F₂N₄O₂S (%):C, 50.00; H, 3.00; N, 16.66. Found (%): C,50.03; H, 3.01; N, 16.64.

4.1.4.12.

3-(4-((2-bromo-4-fluorophenoxy)methyl)-1H-1,2,3-triazol-1-yl)thiophene-2-carboxa mide (5i)

Yield: 73% (0.34g), White solid, M.p.: 147.9-149.5°C. ¹H NMR (600 MHz, DMSO-d₆) $\delta_{\rm H}$: 8.69 (s, 1H), 7.89 (d, J = 5.3 Hz, 1H), 7.86 (s, 1H), 7.68 (s, 1H), 7.57 (dd, J = 8.1, 3.1 Hz, 1H), 7.45 (d, J = 5.3 Hz, 1H), 7.40 (dd, J = 9.1, 4.9 Hz, 1H), 7.26 (m, 1H), 5.30 (s, 2H); ¹³C NMR (100 MHz, DMSO-d₆) $\delta_{\rm C}$: 161.37, 156.11, 151.07, 141.98, 133.46, 128.74, 128.37, 126.41, 125.26, 119.88, 115.29, 115.09, 111.36, 62.51; ESI-MS m/z: 397.4 [M+H]⁺. Anal. calcd. For C₁₄H₁₀BrFN₄O₂S (%):C, 42.33; H, 2.54; N, 14.10. Found (%): C,42.31; H, 2.55; N, 14.12

4.1.4.13.

3-(4-((naphthalen-2-yloxy)methyl)-1H-1,2,3-triazol-1-yl)thiophene-2-carboxamide (5j)

Yield: 76% (0.32g), White solid, M.p.: 161.1-162.8°C. ¹H NMR (600 MHz, DMSO-d₆) $\delta_{\rm H}$: 8.74 (s, 1H), 7.90 (d, J = 5.2 Hz, 1H), 7.85 (m, 4H), 7.68 (s, 1H), 7.56 (d, J = 1.5 Hz, 1H), 7.50 – 7.46 (m, 1H), 7.45 (d, J = 5.2 Hz, 1H), 7.37 (t, J = 7.1 Hz, 1H), 7.23 (m, 1H), 5.34 (s, 2H); ¹³C NMR (100 MHz, DMSO-d₆) $\delta_{\rm C}$: 161.93, 156.42, 142.93, 134.68, 134.08, 129.87, 129.47, 129.12, 128.96, 128.00, 127.26, 126.92, 126.92,125.89, 124.23, 119.12, 107.75, 61.45; ESI-MS m/z: 373.5 [M+Na]⁺. Anal. calcd. For C₁₈H₁₄N₄O₂S (%):C, 61.70; H, 4.03; N, 15.99. Found (%): C, 61.73; H, 4.02; N, 15.97

4.1.4.14.

3-(4-(((4-fluorophenyl)amino)methyl)-1H-1,2,3-triazol-1-yl)thiophene-2-carboxamide (6a)

Yield: 89% (0.33g), Yellow solid, M.p.: 154.1-155.3°C. ¹H NMR (400 MHz, DMSO-d₆) $\delta_{\rm H}$: 8.46 (s, 1H), 7.88 (d, J = 5.3 Hz, 1H), 7.84 (s, 1H), 7.69 (s, 1H), 7.41 (d, J = 5.3 Hz, 1H), 6.93 (t, J = 8.9 Hz, 2H), 6.67 (dd, J = 8.8, 4.5 Hz, 2H), 6.05 (brs, 1H), 4.35 (d, J = 4.4 Hz, 2H); ¹³C NMR (100 MHz, DMSO-d₆) δ c: 161.97, 156.17, 153.87, 145.80, 133.96, 129.14, 129.07, 125.66, 125.07, 115.67, 113.68, 39.39; ESI-MS m/z: 340.4 [M+Na]⁺. Anal. calcd. For C₁₄H₁₂FN₅OS (%):C, 52.99; H, 3.81; N, 22.07. Found (%): C,52.31; H,3.78; N, 22.08

4.1.4.15.

3-(4-(((4-bromophenyl)amino)methyl)-1H-1,2,3-triazol-1-yl)thiophene-2-carboxamid e (**6b**)

Yield: 85% (0.38g), Brown solid, M.p.: 157.7-158.5°C. ¹H NMR (600 MHz, DMSO-d₆) $\delta_{\rm H}$: 8.46 (s, 1H), 7.88 (d, J = 5.2 Hz, 1H), 7.84 (s, 1H), 7.69 (s, 1H), 7.41 (d, J = 5.2 Hz, 1H), 7.21 (d, J = 8.5 Hz, 2H), 6.65 (d, J = 8.5 Hz, 2H), 6.38 (brs, 1H), 4.36 (d, J = 5.1 Hz, 2H); ¹³C NMR (100 MHz, DMSO-d₆) $\delta_{\rm C}$: 161.98, 148.03, 145.74, 133.97, 131.82, 129.14, 129.07, 125.69, 125.10, 114.81, 107.28, 38.70; ESI-MS m/z: 400.3[M+Na]⁺. Anal. calcd. For C₁₄H₁₂BrN₅OS (%):C, 44.46; H, 3.20; N, 18.52. Found (%): C, 44.45; H, 3.23; N, 18.54.

4.1.4.16.

3-(4-(((4-methoxyphenyl)amino)methyl)-1H-1,2,3-triazol-1-yl)thiophene-2-carboxam ide (**6c**)

Yield: 78% (0.30g), Dark yellow solid, M.p.: 185.1-186.7°C. ¹H NMR (600 MHz, DMSO-d₆) $\delta_{\rm H}$: 8.44 (s, 1H), 7.88 (d, J = 5.3 Hz, 1H), 7.85 (s, 1H), 7.69 (s, 1H), 7.41 (d, J = 5.3 Hz, 1H), 6.73 (d, J = 8.8 Hz, 2H), 6.64 (d, J = 8.8Hz, 2H), 5.64 (brs, 1H), 4.33 (s, 2H), 3.64 (s, 3H); ¹³C NMR (100 MHz, DMSO-d₆) $\delta_{\rm C}$: 161.98, 151.57, 151.56, 133.98, 129.13, 129.09, 125.65, 124.98, 115.01, 114.10, 114.08, 55.76, 40.65; ESI-MS m/z: 330.3 [M+H]⁺. Anal. calcd. For C₁₅H₁₅N₅O₂S (%):C, 54.70; H, 4.59; N, 21.26, Found (%): C,54.73; H, 4.61; N, 21.23.

4.1.4.17.*N*-cyclopropyl-3-(4-(((4-(trifluoromethyl)phenyl)amino)methyl)-1H-1,2,3-tri azol-1-yl)thiophene-2-carboxamide (**6d**)

Yield: 83% (0.40g), Yellow solid, M.p.: 160.1-162.3°C. ¹H NMR (600 MHz, DMSO-d₆) $\delta_{\rm H}$: 8.51 (d, J = 2.0 Hz, 1H), 8.40 (s, 1H), 7.85 (d, J = 5.2 Hz, 1H), 7.41 (d, J = 5.2 Hz, 1H), 7.38 (d, J = 8.4 Hz, 2H), 6.93 (t, J = 5.7 Hz, 1H), 6.78 (d, J = 8.4 Hz, 2H), 4.44 (d, J = 5.7 Hz, 2H), 2.69 (m, 1H), 0.61 (m, 2H), 0.41 (m, 2H); ¹³C NMR (100 MHz, DMSO-d₆) $\delta_{\rm C}$: 161.12, 151.15, 144.85, 133.19, 128.08, 127.94, 126.09, 126.06, 124.44, 124.07, 115.60, 111.62, 37.66, 22.80, 5.53; ESI-MS m/z: 430.5[M+Na]⁺. Anal. calcd. For C₁₈H₁₆F₃N₅OS (%):C, 53.07; H, 3.96; N, 17.19. Found (%): C, 53.06; H, 3.98; N, 17.21.

4.1.4.18.

3-(4-(((3,4-difluorophenyl)amino)methyl)-1H-1,2,3-triazol-1-yl)thiophene-2-carboxa mide (**6e**)

Yield: 81% (0.32 g), Pale yellow solid, M.p.: 174.5-175.6°C. ¹H NMR (600 MHz, DMSO-d₆) $\delta_{\rm H}$: 8.53 (s, 1H), 7.94 (d, J = 5.3 Hz, 1H), 7.90 (s, 1H), 7.74 (s, 1H), 7.46 (d, J = 5.3 Hz, 1H), 7.17 (dd, J = 19.9, 9.0 Hz, 1H), 6.72 (m, 1H), 6.51 (d, J = 9.0 Hz, 1H), 6.42 (t, J = 5.8 Hz, 1H), 4.40 (d, J = 5.8 Hz, 2H); ¹³C NMR (100 MHz, DMSO-d₆) $\delta_{\rm C}$: 161.97, 150.41, 146.45, 145.52, 141.75, 133.99, 129.13, 129.04, 125.69, 125.11, 117.82, 108.46, 100.87, 39.03; ESI-MS m/z: 334.5 [M-H]⁻ Anal. calcd. For C₁₄H₁₁F₂N₅OS (%):C, 50.15; H, 3.31; N, 20.89. Found (%): C, 50.12; H, 3.34; N, 20.92

4.1.4.19.

3-(4-(((3-chloro-4-fluorophenyl)amino)methyl)-1H-1,2,3-triazol-1-yl)thiophene-2-car boxamide (**6f**)

Yield: 71% (0.29 g), Yellow solid, M.p.: 151.5-152.5°C. ¹H NMR (600 MHz, DMSO-d₆) $\delta_{\rm H}$: 8.47 (s, 1H), 7.89 (d, J = 5.3 Hz, 1H), 7.85 (s, 1H), 7.68 (s, 1H), 7.41 (d, J = 5.3 Hz, 1H), 7.12 (t, J = 9.1 Hz, 1H), 6.81 (m, 1H), 6.66 – 6.63 (m, 1H), 6.36 (t, J = 5.8 Hz, 1H), 4.36 (d, J = 5.8 Hz, 2H); ¹³C NMR (100 MHz, DMSO-d₆) $\delta_{\rm C}$: 161.97, 149.73, 146.39, 145.53, 133.98, 129.11, 129.04, 125.68, 125.10, 119.83, 117.33, 113.16, 112.51, 38.99; ESI-MS m/z:: 352.4 [M+H]⁺. Anal. calcd. For C₁₄H₁₁ClFN₅OS (%):C,47.80; H,3.15; N, 19.91 Found (%): C,47.78; H, 3.16 N, 19.93.

4.2. hDHODH inhibition assay

Coenzyme Q10 (CoQ10), dichlorophenolindophenol (DCIP) and L-dihvdro orotate (L-DHO) were obtained from Sigma Aldrich. teriflunomide were used as reference compound, which was obtained from Sigma Aldrich. Stock solution of synthesized compounds was retained in DMSO. Recombinant human DHODH was purchased from Prospec Bio (ENZ-642). Inhibitory activity was assessed by monitoring the reduction of 2,6-dichloroindophenol (DCIP), which is associated with oxidation of dihydroorotate catalyzed by the DHODH enzyme. The enzyme was pre-incubated for five minutes at 37 °C in Tris-buffer solution (pH 8.0) with coenzyme Q10 (100 μ M), tested compounds at different concentrations (0.04-10 μ M), and DCIP (50 μ M). The reaction was initiated by addition of DHO (500 μ M) and absorbance of each well was measured at 600 nm. Percent inhibition (max-conversion)/(max-min)*100."max" stands for high control; "min" stands for low control. an IC₅₀ value was calculated using GraphPad Prism software. Values are means \pm SD of two independent experiments.

4.3. Immunosuppression assay

PBMCs were isolated by Ficoll/Isopaque (Lymphoprep) density gradient centrifugation of buffy coat leukopheresis residues from fresh blood samples from healthy donors. Purified cells were grown and maintained in culture medium at 37 $^{\circ}$ C in 5% CO₂ humidified atmosphere. Cell proliferation was assessed by CellTiter-Glo[®]

assay. Cells were seeded in a white-opaque 96-well plate and exposed to increasing concentrations (0.8-200 μ M) of each compound or vehicle (DMSO) for 2 h and then stimulated with 1 μ g/mL anti-CD3 and 2 μ g/mL anti-CD28 for 72 h. IC₅₀ values were determined using nonlinear regression plots with GraphPad Prism software. Values are means \pm SD of two independent experiments.

4.4 Microsomal metabolic stability assay

4.4.1 Solutions preparation

The stock solutions of test article and positive control were prepared at a concentration of 10 mM using DMSO as diluents. All stock solutions were then diluted to working concentrations at 0.25 mM with 70% acetonitrile. The cofactor used in this study was NADPH regenerating system, that was composed of 6.5 mM NADP, 16.5 mM G-6-P, 3 U/mL G-6-PD.The quench reagent was consisted of acetonitrile containing tolbutamide and propanolol (serve as internal standard).The buffer used in this study was 100 mM, phosphate buffer with 3.3 mM MgCl₂. Incubation mixtures containing 0.5 mg/mL liver microsomal protein and 1 μ M test article/positive control in 100 mM potassium phosphate buffer.

4.4.2 Assay procedure

The 0-minute samples were prepared by addition of an 80 μ L aliquot of each incubation mixture to 300 μ L quench reagent to precipitate proteins. The samples were vortexed, and then a 20 μ L aliquot of the NADPH regenerating system was added in. The reaction was initiated by addition of 80 μ L of the NADPH regenerating system to 320 μ L of each incubation mixture. The final incubation conditions achieved in 400 μ L are: 0.5 mg/mL microsomal protein, 1 μ M test article/positive control, 1.3 mM NADP, 3.3 mM glucose 6 phosphate, 0.6 U/mL glucose 6 phosphate dehydrogenase. The mixtures were incubated in a 37°C water bath with gentle shaking. A 100 μ L aliquot of each mixture was removed at 10, 30, 90 minutes to a clean 96-well plate which contains 300 μ L of supernatant are taken into 96-well assay plates pre-added with 160 μ L ultrapure water, and then analyzed by LC-MS/MS.

4.5 Anti-pulmonary fibrotic assay

4.5.1 Cell culture and treatment

The human alveolar epithelial cell line A549 was purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in RPMI-1640 (Hyclone, Logan, UT) containing 10% fetal bovine serum (Hyclone), 100 U/ml penicillin and 100 mg/ml streptomycin (Sigma,St. Louis, MO) in an incubator at 37 °C with 5% CO₂. Cells were rendered quiescent by serum free medium for 24 h, and then pretreated with for 3 h before simulation with 5 ng/ml TGF- β 1 for another 72 h. A549 cells simulated with PBS only were taken as the control.

4.5.2 AFM imaging

Morphological and ultrastructural assays were performed using a Nanoscope VI Dimension 3100 AFM (Veeco Company, Santa Barbara, CA) and oxide-sharpened Si3N4 tips (MLCT, radius 10-40 nm; Bruker Company, Santa Barbara, CA). Cells were seeded in 70 mm culture disk. For living cell imaging, the triangular cantilever with a normal spring constant 0.01 N/m was employed. The spring constant was calibrated with a Thermal Tune Adapter (Veeco Company). The probe was localized onto the cell surface with the assistance of a CCD camera. The experiments were performed at contact mode. The scan force was 50 pN and the scan rate was 0.3 Hz.

4.5.3. Measurement of cellular stiffness by AFM

The stiffness of cells was also detected at contact mode. Measurements were conducted above the nucleus region of the cell to avoid the influence of the underlying substrate. 100 Force-distance curves were obtained from 10 different cells in each group at the ramp rate of 0.5 Hz. Force curves were obtained at the same loading rate and were analyzed by Matlab 7.6.0.

4.6. Molecular Docking

The molecular modelling studies were performed with Accelrys Discovery Studio 3.0. The crystal structure of hDHODH complexed with brequinar (PDB code: 1D3G) was obtained from the RCSB Protein Data Bank (http://www.rcsb.org/pdb/). Compound 5e was drawn with Chemdraw and fully minimized using the CHARMm force field. Before docking, the crystal structure of the protein underwent an optimization process using the Protein Preparation Wizard tool, implemented in Discovery Studio 3.0. Missing hydrogen atoms were added and bond orders were assigned while missing loops and residues not belonging to the binding site were capped by adding ACE (N-acetyl) and NMA (N-methylamide) groups. Then, ORO, nonstructural water molecules and impurities (such as solvent molecules) were removed and the co-crystalized ligand brequinar was maintained. In the docking process, the protein protocol was prepared by several operations, including standardization of atom names and insertion of missing atoms in residues. Then, the receptor model was typed with the CHARMm force field and a binding sphere with radius of 9.0 Å was defined through the original ligand (hydroxylated azole) as the binding site. Finally, they were docked into the binding site using the CDOCKER with the default settings. And figures were prepared using PyMOL (The PyMOL Molecular Graphics System, Version 1.4.1. Schrödinger, LLC).

Conflict of interest

The authors have declared no conflict of interest.

Acknowledgements

We thank the Progarm for Innovation Research Team of the Ministry of Education and Program for Liaoning Innovative Research Team in University

(IR1073) and Shenzhen Science and Technology innovation project (JCYJ20170413113448742) for financial support.

References

[1] M. L. Herrmann, R. Schleyerbach, and B. J. Kirschbaum. Leflunomide: an immune modulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. *Immunopharmacology.*, 47 (2000) 273-289.

[2] M. A. Phillips, and P. K. Rathod. Plasmodium Dihydroorotate Dehydrogenase: A Promising Target for Novel Anti-Malarial Chemotherapy. *Infect. Disord. Drug Targets.*, 10 (2010) 226-239.

[3] D. B. Sykes, Y. S. Kfoury, F. E. Mercier, M. J. Wawer, J. M. Law, E. Jain, M. K. Haynes, T. A. Lewis, A. Schajnovitz, D. Lee, H. Meyer, K. A. Pierce, N. J. Tolliday, A.Waller, S. Ferrara, D. Stoeckigt, K. L. Maxcy, J. M. Cobert, J. Bachand, B. A.Szekely, S.Mukherjee, L. A. Sklar, J. D. Kotz, C. B. Clish, R. I. Sadrayev, P. A. Clemons, A. Janzer, S. L. Schreiber, and D. T. Scadden. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. *Cell.*,167 (2016) 171-186.

[4] C. L. Arteaga, T. D. Brown, J. G. Kuhn, H. S. Shen, T. J. O'Rourke, and K. Beougher. Phase I clinical and pharmacokinetic trial of Brequinar sodium. *Cancer Res.*, 49 (1989) 4648-4653.

[5] J. Leban, W. Saeb, G. Garcia, R. Baumgartner, and B. Kramer. Discovery of a novel series of DHODH inhibitors by a docking procedure and QSAR refinement. *Bioorg. Med. Chem.*, 14 (2004) 55-58.

[6] S. Sainas, A. C. Pippione, M. Giorgis, E. Lupino, P. Goyal, C. Ramondetti, B. Buccinna, M. Piccinini, R. C. Braga, C. H. Andrade, M. Andersson, A. C. Moritzer, R. Friemann, S. Mensa, S. A. Karadaghi, D. Boschi, and M. L. Lolli. Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds. *Eur. J. Med. Chem.*, 129 (2017) 287-302.

[7] F. E. Hahn, V. Langenhahn, N. Meier, T. Lügger, and W. P. Fehlhammer, Template Synthesis of Benzannulated N-Heterocyclic Carbene Ligands, *Chem. Eur. J.* 9 (2003) 704-712.

[8] K. Lamara, A. D. Red house, R. K. Smalley, and J. R. Thompson. 3H-Azepines and Related Systems. Part 5. Photo-induced Ring Expansions of o-Azidobenzouitriles

to 3-Cyano- and 7-Cyano-3H-azepin-2(lH)-ones. *Tetrahedron.*, 50 (1994) 5515-5526. [9] P. F. Wei, X. Z. Yan, J. Y. Li, Y. J. Ma, Y. Yao, F. H. Huang. Novel [2] rotaxanes based on the recognition of pillar [5] arenes to an alkane functionalized with triazole moieties. *Tetrahedron.*, 68 (2012) 9179-9185.

[10] K. C. Majumdar, S. Ganai. An expedient approach to substituted triazolo[1,5-a][1,4]benzodiazepines via Cu-catalyzed tandem Ullmann C–N coupling/azide-alkyne cycloaddition. *Tetrahedron Lett.*, 54 (2013) 6192-6195.

[11] U. Sirion, Y. J. Bae, B. S. Lee, and C. D. Yoon. Ionic polymer supported copper(I): a reusable catalyst for Huisgen's 1,3-dipolar cycloaddition. *Synlett*, 15 (2008) 2326-2330.

[12] F. Himo, T. Lovell, R. Hilgraf, V. V. Rostovtsev, L. Noodleman, K. B. Sharpless, and V. V. Fokin. Copper(I)-Catalyzed Synthesis of Azoles. DFT Study Predicts Unprecedented Reactivity and Intermediates. *J. Am. Chem. Soc.*, 127 (2005) 210-216.

[13] P. Camus, A. Fanton, P. Bonniaud, C. Camus, P. Foucher. Interstitial lung disease induced by drugs and radiation. *Respiration.*, 71 (2004) 301-326.

[14] A. Inoue, Y. Saijo, M. Maemondo, K. Gomi, Y. Tokue, Y Kimura. Severe acute interstitial pneumonia and gefitinib. *Lancet.*, 361 (2003) 137-139.

[15] D. B. Flieder, W. D. Travis. Pathologic characteristics of drug-induced lung disease. *Clin Chest Med.*, 25 (2004) 37-45.

[16] M Liu, M. J. Zheng, H. Y. Xu, L. Q. Liu, Y. C. Li, W Xiao, J. C. Li, and E. L. Ma. Anti-pulmonary fibrotic activity of salvianolic acid B was screened by a novel method based on the cyto-biophysical properties. *Biochem. Bioph. Res. Co.* 468 (2015) 214-220.

[17] S. Liu, E. A. Neidhardt, T. H. Grossman, T. Ocain, J. Clardy. Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. *Structure.*, 8 (2000) 25-33.

- > A novel series of thiophene derivatives were designed, synthesized and evaluated as hDHODH inhibitors
- > Compared with teriflunomide, compound 5e displayed better potency against hDHODH with $IC_{50} 0.9 \mu M$.
- > Compound **5e** also showed high antiproliferative activity against stimulated PBMCs and possessed acceptable metabolic stability
- > Compound **5e** reduced the stiffness of TGF- β 1 stimulated A549 cells similar

d A54

